Electropharmacologic effects of a new phosphodiesterase III inhibitor, toborinone (OPC-18790), assessed in an in vivo canine model

Journal of Cardiovascular Pharmacology

Volumn 38, Issue 2, 2001, Pages 268-277

  Sugiyama, Atsushi ^a   Satoh, Yoshioki ^a   Hashimoto, Keitaro ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Inodilator; Monophasic action potential; Repolarization; Toborinone

Indexed keywords

CYCLIC AMP; PHOSPHODIESTERASE INHIBITOR; SODIUM CHANNEL; TOBORINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR EFFECT; DOG; DRUG BLOOD LEVEL; ENZYME INHIBITION; FEMALE; HEART DEPOLARIZATION; HEART MUSCLE POTENTIAL; HEART OUTPUT; HEART VENTRICLE CONDUCTION; HEART VENTRICLE CONTRACTILITY; MALE; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ACTION POTENTIALS; ANIMALS; BLOOD PRESSURE; CARDIOTONIC AGENTS; DOGS; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HEART RATE; HEMODYNAMIC PROCESSES; MALE; PHOSPHODIESTERASE INHIBITORS; QUINOLONES; VENTRICULAR FUNCTION;

EID: 0034925404     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200108000-00013     Document Type: Article

References (29)

1. Cardiovascular actions of OPC-18790: A novel positive inotropic agent with little chronotropic action
2. Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes
3. Effects of a novel cardiotonic agent (±)-6-[3-(3,4-dimethoxybenzylamino)-2-hydroxypropoxy]-2(1H)- quinolinone (OPC-18790) on contractile force, cyclic AMP level, and aequorin light transients in dog ventricular myocardium
4. Effects of OPC-18790, a new positive inotropic agent, on canine ventricular arrhythmias
5. Acute cardiovascular effects of OPC-18790 in patients with congestive heart failure. Time- and dose-dependence analysis based on pressure-volume relations
6. Effects of a novel inotropic agent (OPC-18790) on systolic and diastolic function in patients with severe heart failure
7. Acute effects of toborinone on vascular capacitance and conductance in experimental heart failure
8. Positive inotropic and chronotropic effects of toborinone and its electrophysiological properties in the isolated hearts of rabbits and guinea-pigs
9. Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: Comparison with quinidine and dofetilide
10. 31P-MRS study
11. A novel inotropic vasodilator, OPC-18790, reduces myocardial oxygen consumption and improves mechanical efficiency with congestive heart failure
12. Differential effects of OPC-18790, amrinone and dobutamine on cardiac function and energy metabolism in the guinea-pig isolated ischemic heart
13. Effects of non-sedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring
14. Effects of gastrointestinal prokinetic agents, TKS 159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring
15. Effects of a class III antiarrhythmic drug, dofetilide, on the in situ canine heart assessed by the simultaneous monitoring of hemodynamic and electrophysiological parameters
16. Effects of magnesium sulfate on the canine cardiovascular system complicating astemizole overdose
17. Bridging the gap between basic and clinical electrophysiology: What can be learned from monophasic action potential recordings?
18. Relation between repolarization and refractoriness during programed electrical stimulation in the human right ventricle
19. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: Antiarrhythmic and proarrhythmic effects
20. OPC-18790, a new positive inotropic agent
21. Effects of toborinone (OPC-18790), a new positive inotropic agent, on action potential in guinea pig sinoatrial node: Compared with milrinone and E-4031
22. OPC-18790, a novel positive inotropic agent, has both arterial and venous vascular dilating actions in the dog
23. Cardiovascular effects of the combination of OPC-18790 and dopamine in halothane-anesthetized dogs
24. Vasorelax action of OPC-18790
25. Utilization of an isolated, blood-perfused canine papillary muscle preparation as a model to assess efficacy and adversity of class I antiarrhythmic drugs
26. Drug-induced torsades de pointes: From molecular biology to bedside
27. Anion and cation modulation of the guinea-pig ventricular action potential during β-adrenoceptor stimulation